Complete Molecular Response Induced by Nilotinib in a Patient Previously Treated With Imatinib, Nilotinib and Dasatinib

Clinical Management Issues - Italy
doi 10.7175/cmi.v7i1s.1143
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Seed SRL

Related search

Evaluation of Nilotinib in Advanced GIST Previously Treated With Imatinib and Sunitinib

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2011English

Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients With Chronic Myeloid Leukemia

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2015English

Major Molecular Response Induced by Nilotinib as First Line Treatment in a LMC Patient With Intermediate Sokal Risk

Clinical Management Issues
MedicineAccountingManagementBusiness
2015English

Response to Imatinib in Villonodular Pigmented Synovitis (PVNS) Resistant to Nilotinib

Clinical Sarcoma Research
Oncology
2013English

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Long-Term Molecular and Cytogenetic Response and Survival Outcomes With Imatinib 400 Mg, Imatinib 800 Mg, Dasatinib, and Nilotinib in Patients With Chronic-Phase Chronic Myeloid Leukaemia: Retrospective Analysis of Patient Data From Five Clinical Trials

The Lancet Haematology
Hematology
2015English

Pancreatic Enzyme Elevation in Chronic Myeloid Leukemia Patients Treated With Nilotinib After Imatinib Failure

Haematologica
Hematology
2009English

Nilotinib Übertrifft Imatinib in Der First-Line Weiterhin

Info Onkologie
2011English

The Third-Time Chronic Myeloid Leukemia in Lymphoblastic Crisis With ABL1 Kinase Mutation Induced by Decitabine, Dexamethason Combined With Nilotinib and Dasatinib

Journal of Translational Internal Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy